164 related articles for article (PubMed ID: 36800717)
1. Association of Hepcidin levels in Type 2 Diabetes Mellitus treated with metformin or combined anti-diabetic agents in Pakistani population.
Najeeb T; Soomro Late MS; Fawwad A; Waris N; Nangrejo R; Siddiqui IA; Aziz Q; Basit A
J Pak Med Assoc; 2023 Feb; 73(2):313-318. PubMed ID: 36800717
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Derosa G; Gaddi AV; Piccinni MN; Salvadeo S; Ciccarelli L; Fogari E; Ghelfi M; Ferrari I; Cicero AF
Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
[TBL] [Abstract][Full Text] [Related]
3. Circulating hepcidin in type 2 diabetes: A multivariate analysis and double blind evaluation of metformin effects.
Suárez-Ortegón MF; Moreno M; Arbeláez A; Xifra G; Mosquera M; Moreno-Navarrete JM; Aguilar-de Plata C; Esteve E; Ricart W; Fernández-Real JM
Mol Nutr Food Res; 2015 Dec; 59(12):2460-70. PubMed ID: 26394887
[TBL] [Abstract][Full Text] [Related]
4. Triglyceride-glucose index: A surrogate marker of homeostasis model assessment of insulin resistance to predict diabetic nephropathy.
Khan S; Qayyum S; Khan MNA
J Pak Med Assoc; 2024 May; 74(5):862-867. PubMed ID: 38783431
[TBL] [Abstract][Full Text] [Related]
5. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
6. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
8. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
10. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
[TBL] [Abstract][Full Text] [Related]
13. Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity.
Andrews M; Soto N; Arredondo-Olguín M
Nutrition; 2015 Jan; 31(1):51-7. PubMed ID: 25441587
[TBL] [Abstract][Full Text] [Related]
14. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study.
Mo D; Liu S; Ma H; Tian H; Yu H; Zhang X; Tong N; Liao J; Ren Y
Drug Des Devel Ther; 2019; 13():2769-2776. PubMed ID: 31496653
[TBL] [Abstract][Full Text] [Related]
15. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
16. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2.
Dong M; Gong ZC; Dai XP; Lei GH; Lu HB; Fan L; Qu J; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):824-9. PubMed ID: 21933224
[TBL] [Abstract][Full Text] [Related]
17. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
18. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
[TBL] [Abstract][Full Text] [Related]
19. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
20. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
